Get started
Author

Mary Jane Hinrichs

Observed names: Hinrichs Mary Jane, Mary Jane Masson Hinrichs, Mary Jane Hinrichs
ORCID: 0000-0002-3816-2334
Observed ORCID: 0000-0002-3816-2334
OpenAlex ID: A5083508937
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
2016 · John Y. Li, Samuel R. Perry, et al. · Cancer Cell · 410
PDF
Antibody Drug Conjugates: Nonclinical Safety Considerations
2015 · Mary Jane Masson Hinrichs, Rakesh Dixit · The AAPS Journal · 117
PDF
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
2021 · Johann S. de Bono, Mark T. Fleming, et al. · Clinical Cancer Research · 59
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics
2016 · Pamela Thompson, Ryan Fleming, et al. · Journal of Controlled Release · 57
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
2018 · Song Cho, Francesca Zammarchi, et al. · Molecular Cancer Therapeutics · 50
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates
2017 · Mary Jane Masson Hinrichs, Pauline M. Ryan, et al. · Clinical Cancer Research · 48
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
2017 · Jay Harper, Christopher Lloyd, et al. · Molecular Cancer Therapeutics · 48
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses
2018 · Bo Chen, Katherine A Vousden, et al. · Annals of the Rheumatic Diseases · 39
PDF
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
2019 · John Y. Li, Samuel R. Perry, et al. · Cancer Cell · 36
PDF
Interpreting and Integrating Clinical and Anatomic Pathology Results: Pulling It All Together
2016 · Lila Ramaiah, Mary Jane Hinrichs, et al. · Toxicologic Pathology · 33
PDF
Patient Selection Strategies to Maximize Therapeutic Index of Antibody–Drug Conjugates: Prior Approaches and Future Directions
2020 · Marna Williams, Anna Spreafico, et al. · Molecular Cancer Therapeutics · 26
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer
2019 · Jason B. White, Ryan Fleming, et al. · mAbs · 24
PDF
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials
2015 · Aaron R. Hansen, Natalie Cook, et al. · The Oncologist · 24
HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells
2021 · Leiming Xia, Lu Wen, et al. · Cell chemical biology · 19
PDF
Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety
2014 · Patricia C. Ryan, Matthew A. Sleeman, et al. · Toxicology and Applied Pharmacology · 19
PDF
Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers
2018 · Nabendu Pore, Kevin P Schifferli, et al. · Blood · 9
Abstract 2970: MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent in vitro and in vivo activity in preclinical studies
2016 · John Li, Dorin Toader, et al. · Cancer Research · 8
Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar proteinosis phenotype but does alter lung surfactant turnover
2021 · Dominic J. Corkill, Alan N. Hunt, et al. · Clinical Science · 3
Safety Assessment Strategies and Predictive Safety of Biopharmaceuticals and Antibody Drug Conjugates
2016 · Michelle J. Horner, Mary Jane Hinrichs, et al. · Wiley eBooks · 2
Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models
2018 · Song Cho, Francesca Zammarchi, et al. · Cancer Research · 1
Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers
2017 · Francesca Zammarchi, Simon Chivers, et al. · Cancer Research · 1
Abstract 948: A novel antibody-drug conjugate that induces long-term tumor regression and anticancer stem cell activity
2015 · Jay W. Harper, Chris Lloyd, et al. · Cancer Research · 1
Abstract ND12: Development of IPN01203, a dual T cell agonist activating Vβ6/Vβ10 TCR-expressing T cells
2026 · Enguerran Mouly, Karen Bunting, et al. · Cancer Research
Abstract 4444: Integrin alpha-2 (ITGA2) is a novel and well-suited antibody-drug conjugate (ADC) target
2026 · Sophie Colombo, Vincent Martin, et al. · Cancer Research
Abstract 1665: Preclinical characterization of IPN60300, a first-in-class ITGA2 antibody-drug conjugate for cancer therapy
2026 · Aurélie Courtin, Benjamin Beaufils, et al. · Cancer Research
Works count: 51
Citation count: 1,034
H-index: 15
I10-index: 15
Year
Topic
Type